Sort   by:  
 Page size 
UnknownDouble-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Not available
S-EPMC4104290 | biostudies-literature
UnknownChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Not available
S-EPMC5891129 | biostudies-literature
UnknownSeven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Not available
S-EPMC5805480 | biostudies-literature
UnknownRandomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer.
Not available
S-EPMC5791829 | biostudies-literature
UnknownA randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
Not available
S-EPMC4142676 | biostudies-literature
UnknownPatterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
Not available
S-EPMC7738423 | biostudies-literature
UnknownA phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Not available
S-EPMC3457748 | biostudies-literature
UnknownTrait sensitivity to social disconnection enhances pro-inflammatory responses to a randomized controlled trial of endotoxin.
Not available
S-EPMC4637264 | biostudies-literature
UnknownIs there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Not available
S-EPMC4720089 | biostudies-literature
UnknownAIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.
Not available
S-EPMC3360823 | biostudies-literature
Sort   by:  
 Page size